PFBT
RXRX icon

Parkside Financial Bank & Trust’s Recursion Pharmaceuticals RXRX Stock Holding History

Parkside Financial Bank & Trust’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.34K Sell
2,000
-110
-5% -$366 ﹤0.01% 1759
2026
Q1 		$6.48K Hold
2,110
– – ﹤0.01% 1739
2025
Q4 		$8.63K Sell
2,110
-9
-0.4% -$45 ﹤0.01% 1630
2025
Q3 		$10.3K Buy
2,119
+2,019
+2,019% +$10.6K ﹤0.01% 1507
2025
Q2 		$506 Sell
100
-65
-39% -$319 ﹤0.01% 2548
2025
Q1 		$873 Buy
+165
New +$1.2K ﹤0.01% 2161

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Parkside Financial Bank & Trust's RXRX Position: Q2 2026 in Review

Parkside Financial Bank & Trust reduced its Recursion Pharmaceuticals (RXRX) stake by 5.2% in Q2 2026, selling an estimated $366 and leaving 2,000 shares worth $7.34K. The position accounts for ﹤0.01% of the portfolio, ranked #1759.

Parkside Financial Bank & Trust first reported a position in RXRX in Q1 2025 and has held it in 6 quarters since. The position peaked at $10.3K in Q3 2025. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Parkside Financial Bank & Trust held 2,000 shares of Recursion Pharmaceuticals worth $7.34K as of Q2 2026.
  • Parkside Financial Bank & Trust sold 110 Recursion Pharmaceuticals shares in Q2 2026, an estimated $366.
  • Recursion Pharmaceuticals made up ﹤0.01% of Parkside Financial Bank & Trust's portfolio in Q2 2026, its #1759 holding.
  • Parkside Financial Bank & Trust first reported a position in Recursion Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • Parkside Financial Bank & Trust's Recursion Pharmaceuticals position peaked at $10.3K in Q3 2025.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q2 2026, filed 4 Sep 2026.